3-arm bio study [Design Issues]

posted by rocky – 2013-06-19 21:59 (4754 d 23:56 ago) – Posting: # 10830
Views: 4,472

Hello Everyone...

Can anyone through some light on the below issue please?


I am currently running a DCP procedure (1 RMS, 5 X CMS’s) for an X product in EU to secure MA for four different strengths (2.5mg, 5mg, 7.5mg and 10mg). Reference product is only available for higher strength so I applied higher strength application as 10.1 and other 3 strengths application as hybrid . WHO guidelines and available literature suggested that bio study is not required so I went a head and submitted application without a bio study. Now authorities requested us to do a bio study on higher and lower strength citing it’s non-linearity, variable absorption and also because of its AUC (it increases with less than proportional with increasing dose.)


My question is whether a three arm bio study (2.5mg x 4 vs 10mg (Test) vs 10mg (Ref) is acceptable on the above case and whether authorities allow to use two reference products (RMP & ERP) on the same DCP procedure?

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,570 registered users;
202 visitors (0 registered, 202 guests [including 20 identified bots]).
Forum time: 21:55 CEST (Europe/Vienna)

Ignorance more frequently begets confidence
than does knowledge.    Charles Darwin

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5